Screener
CRISPR Therapeutics CRSP Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Cash and cash equivalents | $423,308 | $347,559 |
| Marketable securities | 2,018,477 | 1,628,269 |
| Prepaid expenses and other current assets | 6,577 | 9,843 |
| Total current assets | 2,448,362 | 1,985,671 |
| Property and equipment, net | 112,175 | 115,851 |
| Restricted cash | 7,629 | 7,629 |
| Operating lease assets | 128,671 | 131,724 |
| Other non-current assets | 28,983 | 24,368 |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's total current assets?
- CRISPR Therapeutics (CRSP) reported total current assets of $2.45B in Q1 2026.
- How has CRISPR Therapeutics's total current assets changed year-over-year?
- CRISPR Therapeutics's total current assets increased by 31.1% year-over-year, from $1.87B to $2.45B.
- What is the long-term trend for CRISPR Therapeutics's total current assets?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's total current assets has grown at a 3.0% compound annual growth rate (CAGR), from $1.72B to $1.99B.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about CRISPR Therapeutics's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude